Association between vitamin D and prediabetes

Lu, Yu; Zhai, Yu; Shen, Shanmei

doi:10.1097/md.0000000000019034

Cited by 25 publications

(25 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the serum levels of 25(OH)D, vitamin D nutritional status has been classified as deficient (<20 ng/mL), insufficient (21-29 ng/mL), and sufficient (>30 ng/mL) [2]. Recent evidence has shown an association of vitamin D deficiency with several metabolic disturbances such as metabolic syndrome (MetS), high blood pressure (BP), type 2 diabetes (T2D), insulin resistance (IR), and obesity [14][15][16][17][18]. Diverse studies have suggested that vitamin D deficiency could promote adipogenesis and disturb the metabolism involved in energy homeostasis, such as leptin, adiponectin, and resistin [19][20][21].…”

Section: Introductionmentioning

confidence: 99%

Total, Bioavailable, and Free 25-Hydroxyvitamin D Equally Associate with Adiposity Markers and Metabolic Traits in Mexican Adults

et al. 2021

View full text Add to dashboard Cite

Epidemiological studies suggest a relationship between total 25-hydroxyvitamin D [25(OH)D], adiposity, and metabolic traits. The bioavailability of 25(OH)D is regulated by the albumin, vitamin D binding protein (VDBP), and variants of the GC gene. Therefore, it is not clear if bioavailable or free 25(OH)D offer additional benefits compared to total 25(OH)D when estimating the magnitude of these associations. Our aim was to evaluate the association between 25(OH)D (total, free and bioavailable) with adiposity and metabolic traits. This was a cross-sectional study of 1904 subjects from the Health Workers Cohort Study from Mexico. Free and bioavailable 25(OH)D were calculated based on VDBP and albumin determinations, using a formula adjusted for the GC gene diplotypes. Adiposity and metabolic traits were measured with standardized procedures. Free and bioavailable 25(OH)D levels correlated with total 25(OH)D, r = 0.71 and 0.70, respectively (p < 0.001). Total, bioavailable and free 25(OH)D levels were negatively associated with the adiposity marker (visceral adiposity index) and metabolic traits (metabolic syndrome, type 2 diabetes, triglycerides, triglycerides/HDL-c ratio, and triglycerides/glucose index) in multivariate regression models (ORs = 0.73 to 0.96). Our findings suggest that free and bioavailable 25(OH)D do not offer additional advantages over total 25(OH)D regarding its association with adiposity and several metabolic traits in Mexican adults.

show abstract

Section: Introductionmentioning

confidence: 99%

Total, Bioavailable, and Free 25-Hydroxyvitamin D Equally Associate with Adiposity Markers and Metabolic Traits in Mexican Adults

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Studies on the effects of vitamin D on insulin sensitivity have been inconsistent [34,35]. Although it has been proposed that vitamin D deficiency plays an important role in IR [36], many factors are involved, including age, obesity and the presence of prediabetes as well as other cardiovascular risk factors [37]. Inconsistent results between vitamin E and IR have also been reported [38,39].…”

Section: Discussionmentioning

confidence: 99%

An Open Pilot Study of the Effect and Tolerability of Add-On Multivitamin Therapy in Patients with Intractable Focal Epilepsy

et al. 2020

View full text Add to dashboard Cite

Observational studies have investigated the potential modulatory effect of neuronal excitability by vitamins in epilepsy. We aimed to investigate whether the addition of multivitamin therapy (B6/B9, D, E and Q) to regular antiepileptic drug therapy could ameliorate seizures in patients with refractory focal epilepsy. We conducted a prospective cohort open study to investigate the effect and tolerability of add-on multivitamin therapy (daily dose: B6 100 mg, B9 5 mg, D 1000 IU, E 400 IU and coenzyme Q10 100 mg) in patients with intractable focal epilepsy. All patients had effect and safety assessments at baseline and after one, three and six months of the supplementation. Thirty patients (11 men and 19 women) with a mean age of 42.37 ± 9.40 years were recruited and four patients discontinued. The seizure frequency significantly decreased after the six-month supplementation (9.04 ± 18.16/month and 2.06 ± 3.89/month, p = 0.045). At the final visit, 62.5% of the patients showed a ≥50% reduction in seizure frequency, and 12.5% were seizure-free. As to safety and tolerability, most patients did not experience significant adverse events, although three patients reported seizure worsening. In conclusion, this pilot study demonstrated the therapeutic potential and essentially good tolerability of add-on multivitamin therapy in patients with refractory focal epilepsy.

show abstract

“…A four-year followup study suggested that low levels of serum 25(OH)D might be linked to the increased incidence of prediabetes or T2DM in Chinese individuals [5]. Two meta-analyses observed that the administration of vitamin D led to a reduction in glucose and hemoglobin A1c (HbA1c), regardless of intramuscular injection and oral supplementation [6,7]. Therefore, more randomized controlled trials (RCTs) are needed to explore the association between vitamin D supplementation and prediabetes.…”

Section: Introductionmentioning

confidence: 99%

Effect of Vitamin D Supplementation on Glycemic Control in Prediabetes: A Meta-Analysis

et al. 2021

View full text Add to dashboard Cite

Clinical research results of vitamin D supplementation in the improvement of prediabetes remain controversial. Accordingly, a literature search was conducted of PubMed, Embase (Ovid), and Web of Science prior to 9 November 2021. Randomized controlled studies reported that the following indicators were included: body mass index (BMI), fasting blood glucose (FBG), 2 h oral glucose tolerance test plasma glucose (2h-PG), hemoglobin A1c (HbA1c), insulin resistance by homeostasis model assessment (HOMA-IR), homeostasis model assessment of β-cell function (HOMA-B), and fasting insulin (FINS). Twenty-nine articles (N = 3792) were included in the present meta-analysis. Intriguingly, vitamin D supplementation resulted in a vast improvement in FBG (standardized mean difference (SMD) = −0.38; 95%CI: −0.59, −0.16), HbA1c (SMD = −0.14; 95%CI: −0.22, −0.06) and FINS (SMD = 0.18; 95%CI: −0.26, −0.09), but not in other outcomes. However, preferred changes were observed in subgroups, as follows: Asia (SMD2h-PG = −0.25, 95%CI: −0.45, −0.04), study duration ≥1 year (SMDHOMA-IR = −0.44, 95%CI: −0.81, −0.06) (SMDHOMA-B = 0.34, 95%CI: 0.01, 0.66), baseline 25(OH)D < 50 nmol/L (SMD2h-PG = −0.23, 95%CI: −0.39, −0.06), and baseline 25(OH)D ≥ 50 nmol/L (SMDHOMA-IR = −0.50, 95%CI: −0.96, −0.03). In conclusion, oral supplementation of vitamin D has shown better effects in improving FBG, HbA1c, and FINS compared with controls among prediabetics; long-term vitamin D supplementation could have additional effects in participants with vitamin D deficiency for 2h-PG, HOMA-IR, and HOMA-B.

show abstract

Association between vitamin D and prediabetes

Cited by 25 publications

References 20 publications

Total, Bioavailable, and Free 25-Hydroxyvitamin D Equally Associate with Adiposity Markers and Metabolic Traits in Mexican Adults

Total, Bioavailable, and Free 25-Hydroxyvitamin D Equally Associate with Adiposity Markers and Metabolic Traits in Mexican Adults

An Open Pilot Study of the Effect and Tolerability of Add-On Multivitamin Therapy in Patients with Intractable Focal Epilepsy

Effect of Vitamin D Supplementation on Glycemic Control in Prediabetes: A Meta-Analysis

Contact Info

Product

Resources

About